Novo Nordisk A/S
Amgen, newer rivals could threaten Novo Nordisk and Eli Lilly’s weight loss drug dominance
The injectable weight-loss medication Wegovy is available at New City Halstead Pharmacy on April 24, 2024 in Chicago, Illinois. Scott Olson | Getty Images Novo Nordisk and Eli Lilly have long dominated the rapidly growing weight loss drug market, but their duopoly is closer than ever to facing a threat from a new rival. Amgen […]
Read More
Amgen stock soars on weight loss injection progress as Novo Nordisk, Eli Lilly shares slide
Pavlo Gonchar | Lightrocket | Getty Images Amgen‘s stock rose more than 12% on Friday after the drugmaker teased positive initial data on its experimental weight loss injection. That fueled investor concerns about new competition in the rapidly growing weight loss drug industry, sending shares of the current obesity players, Novo Nordisk and Eli Lilly, […]
Read More
Wegovy maker Novo Nordisk down 4%, heads for worst day considering the fact that Oct
Shares of Danish pharmaceutical giant Novo Nordisk slid 4% on Friday, extending a 2.7% decline on Thursday as analysts pored about the facts of the firm’s first-quarter final results and monitored a opportunity rival body weight reduction procedure. It puts the stock on observe for its sharpest everyday drop considering the fact that Oct 2023, in accordance to […]
Read More
Shares earning the largest moves premarket: Apple, Amgen, Cloudflare and more
Examine out the companies creating headlines before the bell. Hershey — Shares of the chocolate confectionary maker additional about 1% right after Hershey posted a very first-quarter earnings defeat. The company described altered earnings of $3.07 per share, which came earlier mentioned the $2.76 for each share analysts polled by LSEG experienced predicted. Hershey’s $3.25 […]
Read More
Amgen scraps experimental weight loss pill, moves forward with injection
The Amgen logo is displayed outside Amgen headquarters in Thousand Oaks, California, on May 17, 2023. Mario Tama | Getty Images Amgen on Thursday said it will stop developing its experimental weight loss pill and instead move forward with its injectable drug and other products in development for obesity. The announcement is a setback for […]
Read More
Novo Nordisk beats financial gain estimates as income of pounds loss drug Wegovy additional than double
The injectable bodyweight-loss medication Wegovy is obtainable at New Town Halstead Pharmacy on April 24, 2024 in Chicago, Illinois. Scott Olson | Getty Photos Novo Nordisk, which turned the most worthwhile firm in Europe final calendar year due to the blockbuster accomplishment of its weight loss medications, on Thursday beat very first-quarter financial gain anticipations […]
Read More
FTC challenges ‘junk’ patents held by 10 drugmakers, including for Novo Nordisk’s Ozempic
A box of Ozempic and contents sit on a table in Dudley, North Tyneside, Britain, October 31, 2023. Lee Smith | Reuters The Federal Trade Commission on Tuesday said it is challenging hundreds of alleged “junk” patents held by pharmaceutical companies for 20 brand-name drugs, including Novo Nordisk’s blockbuster drugs Ozempic, Saxenda and Victoza. The […]
Read More
Eli Lilly assures investors it can overcome the high-quality problem of too much demand
Eli Lilly ‘s raised guidance stole the show Tuesday, offsetting mixed first-quarter results and propelling shares higher by nearly 6%. The numbers leave little doubt that the long-term Eli Lilly success story remains intact, as demand for its new diabetes and obesity drugs, Mounjaro and Zepbound, outstrips supply. Revenue in the three months ended March […]
Read More
Senate launches investigation into high prices of Ozempic and Wegovy in the U.S.
The anti-diabetic medicine “Ozempic” (semaglutide) built by Danish pharmaceutical corporation Novo Nordisk. Joel Saget | AFP | Getty Illustrations or photos The U.S. Senate has launched an investigation into the high rate of Novo Nordisk‘s preferred fat decline and diabetes drugs Ozempic and Wegovy in the United States. The investigation into the Danish drugmaker was […]
Read More
More than 3 million Medicare patients could be eligible for coverage of Wegovy to reduce heart disease risks, study says
More than 3 million people with Medicare could be eligible for coverage of Wegovy now that the blockbuster weight loss drug is also approved in the U.S. for heart health, according to an analysis released Wednesday by health policy research organization KFF. But some eligible beneficiaries could still face out-of-pocket costs for the highly popular […]
Read More